uniQure N.V.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Shows how the company funds its gene therapy research and how costs are organized for investors to track.
Investors learn quarterly performance and company updates to understand if the business is growing or shrinking.
New money raised helps fund drug development but dilutes existing shareholders' ownership stakes.
Legal document showing what securities the company may sell and where investor money could go.
Gives company flexibility to raise money quickly if needed for research, drug trials, or operations.
Successful early trial results make the drug more valuable and increase chances of FDA approval and sales.
FDA approval path clears way for potential product launch, which could generate revenue for the company.
Stocky reads uniQure N.V.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
uniQure N.V.'s most recent tracked filing was a 10-Q on 29 Jul 2026: Reports Q2 2026 results with European research subsidies.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.